Medtronic agrees to buy carotid stent maker Contego Medical for $380 million
Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.
How this was made
The 30-second read
Why it matters
The acquisition adds newly FDA-approved carotid revascularization technology with integrated embolic protection and positions Excipio alongside Medtronic’s Liberant system, with management guiding minimal dilution to adjusted EPS in FY27-28 and neutral to accretive effects after that.
Market read
Traders can reassess Medtronic’s growth outlook and deal economics ahead of expected fiscal Q3 closing, using the disclosed purchase price and EPS dilution/accretion guidance.
What to watch
Contingent payments and the lack of disclosed upfront versus contingent split could increase uncertainty around total consideration and near-term cash flow.
Background
Medtronic has been a minority investor in Contego since 2020 and previously announced an exclusive US distribution agreement in January 2025.
Ticker impact
Medtronic agreed to buy Contego Medical for $380 million, adding the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.
Likely positive bias as investors price in expanded device portfolio and a path to accretion after closing.
The article discloses a specific acquisition price, included FDA-approved products, and stated EPS dilution expectations (minimal in FY27-28, neutral to accretive thereafter), which are direct inputs to valuation and deal-risk assessment.
Market effects
Strengthens Medtronic’s position in carotid revascularization and thrombectomy devices, potentially increasing competitive pressure in peripheral vascular interventions.
Primarily US medtech market impact via FDA-approved device commercialization and distribution expansion.
Could influence global peripheral vascular device competitive dynamics if the acquired platform scales beyond the US.
Counterpoint
The deal’s value may be less compelling if integration and regulatory or reimbursement dynamics delay commercialization of Neuroguard and Excipio.
Key entities
- companyMedtronic
US-listed medical device company agreeing to acquire Contego for $380 million.
- companyContego Medical
Privately held carotid stent and thrombectomy device maker; seller in the transaction.
- productNeuroguard IEP Direct System
FDA-approved transcarotid artery revascularization system with integrated embolic protection and flow reversal.
- productExcipio thrombectomy devices
Thrombectomy devices included in the acquisition, to sit alongside Medtronic’s Liberant system.


